ASTRIA THERAPEUTICS INC
NASDAQ: ATXS (Astria Therapeutics, Inc.)
Last update: 6 hours ago5.81
0.08 (1.40%)
| Previous Close | 5.73 |
| Open | 5.80 |
| Volume | 188,854 |
| Avg. Volume (3M) | 503,280 |
| Market Cap | 327,882,688 |
| Price / Book | 1.69 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 17.39 |
| Operating Cash Flow (TTM) | -96.14 M |
| Levered Free Cash Flow (TTM) | -62.11 M |
| Return on Assets (TTM) | -22.56% |
| Return on Equity (TTM) | -32.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Astria Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 1.50 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.49% |
| % Held by Institutions | 106.43% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 47.00 (Cantor Fitzgerald, 708.95%) | Buy |
| Median | 31.50 (442.17%) | |
| Low | 16.00 (HC Wainwright & Co., 175.39%) | Buy |
| Average | 31.50 (442.17%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 4.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Jun 2025 | 16.00 (175.39%) | Buy | 5.72 |
| Cantor Fitzgerald | 14 May 2025 | 47.00 (708.95%) | Buy | 3.97 |
| 29 Apr 2025 | 47.00 (708.95%) | Buy | 5.12 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |